Theophylline

Evidence Level: L5

Predicted Indications: 6

Theophylline

Pharmacist Assessment Report

Theophylline: From Asthma to Thrombotic Disease

One-Sentence Summary

Theophylline is a xanthine bronchodilator, recorded in the knowledge graph as being used for asthma, bronchitis and emphysema. The TxGNN model predicts it may be effective for thrombotic disease, but there are 0 registered clinical trials and no retrieved publication that directly studies this use, so the prediction rests on the model score and a theoretical mechanism alone.

Quick Overview

Item	Content
Original Indication	Asthma, bronchitis, pulmonary emphysema and related lung disease (relations recorded in the knowledge graph; the Australian licence record contains no indication text)
Predicted New Indication	Thrombotic disease
TxGNN Prediction Score	0.9962
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Theophylline is generally known as a non-selective phosphodiesterase (PDE) inhibitor and adenosine receptor antagonist. PDE inhibition raises cAMP in platelets, which could in theory reduce platelet aggregation. This is the most plausible basis for the high prediction score.

The mechanism is not straightforward, however. Adenosine receptor antagonism could oppose adenosine’s own antiplatelet effect. No retrieved paper shows a clinical antithrombotic benefit of theophylline. The link between its respiratory use and thrombosis is therefore a model-derived hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Nineteen publications were retrieved, but none directly studies theophylline for thrombotic disease. Most concern platelet biology, laboratory methods or other drugs. Representative examples are below.

PMID	Year	Type	Journal	Key Findings
8055680	1994	Review	Clinical Pharmacokinetics	Pharmacokinetics of ticlopidine, a different antiplatelet drug; not about theophylline
6771102	1980	Review	CRC Critical Reviews in Biochemistry	Prostaglandins, platelets and atherosclerosis; background on platelet cAMP signalling
8981060	1996	Laboratory study	General Pharmacology	Milrinone (a PDE inhibitor) inhibits human platelet aggregation and interacts with adenosine; indirect mechanistic relevance only
21719422	2011	Cohort	Rheumatology (Oxford)	Platelet and neutrophil activation in Behçet’s disease; not about theophylline
15475744	2004	Cohort	Inflammatory Bowel Diseases	Platelet-leukocyte aggregates in inflammatory bowel disease; not about theophylline
749930	1978	Laboratory method	British Journal of Haematology	Theophylline used only as a sample-collection additive in a platelet factor 4 assay
29254574	2018	Analytical method	Analytica Chimica Acta	Aptasensor for detecting theophylline; no clinical relevance to thrombosis

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 2614N	Nuelin	Oral solution 133.3 mg per 25 mL, 500 mL	Not stated in the licence record

Safety Considerations

Contraindication-type relations recorded in the knowledge graph (not label text): hypertension, liver failure and liver disease, epilepsy, anxiety and other mental disorders, porphyria, kidney disease, hypothyroidism, peptic ulcer disease, open-angle glaucoma, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, thrombocytopenia, neutropenia and agranulocytosis.

Drug interactions: 100 interactions were recorded. The ones shown include:

Major: bupropion
Moderate: famotidine, ranitidine, cimetidine, omeprazole, rabeprazole, clarithromycin, doxycycline, tetracycline, minocycline, and corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide)
Minor: ephedrine

Theophylline has a narrow therapeutic window, so serum level monitoring is relevant. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The high TxGNN score is not supported by any registered trial or any publication directly studying theophylline in thrombotic disease. The PDE-inhibition mechanism is plausible, but adenosine antagonism may work against it, and the evidence level is L5.

To proceed, the following is needed:

Detailed mechanism of action data and a focused analysis of platelet and thrombosis effects
Preclinical or ex vivo platelet aggregation data for theophylline at clinically achievable concentrations
Review of the TGA Product Information for warnings and contraindications
A safety assessment of the narrow therapeutic window and the many interactions in patients likely to need antithrombotic therapy

Other Predicted Indications (Brief Notes)

Rank	Predicted Indication	Score	Evidence Level	Note
2	Nasal cavity disease	0.9953	L5	One small human nasal allergen challenge study in allergic rhinitis (PMID 9648963); design not confirmed; no registered trials
3	Laryngotracheitis	0.9951	L5	No trials or literature
4	Tracheal disease	0.9949	L3	Preclinical tracheal relaxation studies and a veterinary retrospective study in dogs (PMID 31565900); no human trial
5	Pharyngitis	0.9946	L4 as supplied	No retrieved study directly addresses theophylline in pharyngitis, so by the evidence ceiling rule this should be treated as L5
6	Acute laryngopharyngitis	0.9935	L5	No trials or literature

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.